People: Atara Biotherapeutics Inc (ATRA.OQ)

ATRA.OQ on NASDAQ Stock Exchange Global Select Market

1:30am IST
Change (% chg)

$-0.17 (-1.12%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Gallagher, Carol 

Dr. Carol G. Gallagher, Pharm.D. is the Lead Independent Director of the Company. Since October 2014, Dr. Gallagher has served as a partner with New Enterprise Associates, a venture capital firm. Prior to joining New Enterprise Associates, Dr. Gallagher served as a venture partner with Frazier Healthcare, a venture capital firm, from October 2013 to September 2014. Dr. Gallagher served as the President and Chief Executive Officer of Calistoga Pharmaceuticals, a biopharmaceutical company, from 2008 to 2011, when the company was acquired by Gilead Sciences. From 2007 to 2008, Dr. Gallagher was the President and Chief Executive Officer of Metastatix, Inc., a biopharmaceutical company. Prior to that time starting in 1989, she served in various roles at pharmaceutical companies Eli Lilly, Amgen, Agouron Pharmaceuticals, Pfizer, Biogen Idec Pharmaceuticals, CancerVax and Anadys Pharmaceuticals. Dr. Gallagher attended Vanderbilt University and received B.S. and Doctor of Pharmacy degrees from the University of Kentucky. We believe that Dr. Gallagher is qualified to serve on our Board due to her extensive experience in the pharmaceuticals industry, her leadership and management experience, and her service as a director of other biopharmaceutical companies.

Basic Compensation

Total Annual Compensation, USD 72,500
Restricted Stock Award, USD 68,475
Long-Term Incentive Plans, USD --
All Other, USD 128,281
Fiscal Year Total, USD 269,256

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Pascal Touchon


Utpal Koppikar


Joseph Newell


Mina Kim


Derrell Porter


Dietmar Berger

As Of  31 Dec 2018